Rodrigo Hernandez Canteli

Leveraging information in real-world data, literature, and omics with artificial intelligence and engaging human expertise to expand the knowledge frontier of molecules by innovating in indication discovery to accelerate programs' potential, de-risk drug development, and raise asset value. Our expertise closes the translational gap between advanced analytics, complex biology, and market dynamics, providing our pharmaceutical and biotechnological partners with a holistic strategic roadmap of their assets and bringing treatments to patients sooner.